1
|
Padilla-Godínez FJ, Ruiz-Ortega LI, Guerra-Crespo M. Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes. Cells 2022; 11:3445. [PMID: 36359841 PMCID: PMC9657131 DOI: 10.3390/cells11213445] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 10/18/2022] [Accepted: 10/26/2022] [Indexed: 01/02/2024] Open
Abstract
The complexity and overall burden of Parkinson's disease (PD) require new pharmacological approaches to counteract the symptomatology while reducing the progressive neurodegeneration of affected dopaminergic neurons. Since the pathophysiological signature of PD is characterized by the loss of physiological levels of dopamine (DA) and the misfolding and aggregation of the alpha-synuclein (α-syn) protein, new proposals seek to restore the lost DA and inhibit the progressive damage derived from pathological α-syn and its impact in terms of oxidative stress. In this line, nanomedicine (the medical application of nanotechnology) has achieved significant advances in the development of nanocarriers capable of transporting and delivering basal state DA in a controlled manner in the tissues of interest, as well as highly selective catalytic nanostructures with enzyme-like properties for the elimination of reactive oxygen species (responsible for oxidative stress) and the proteolysis of misfolded proteins. Although some of these proposals remain in their early stages, the deepening of our knowledge concerning the pathological processes of PD and the advances in nanomedicine could endow for the development of potential treatments for this still incurable condition. Therefore, in this paper, we offer: (i) a brief summary of the most recent findings concerning the physiology of motor regulation and (ii) the molecular neuropathological processes associated with PD, together with (iii) a recapitulation of the current progress in controlled DA release by nanocarriers and (iv) the design of nanozymes, catalytic nanostructures with oxidoreductase-, chaperon, and protease-like properties. Finally, we conclude by describing the prospects and knowledge gaps to overcome and consider as research into nanotherapies for PD continues, especially when clinical translations take place.
Collapse
Affiliation(s)
- Francisco J. Padilla-Godínez
- Neurosciences Division, Cell Physiology Institute, National Autonomous University of Mexico, Coyoacan, Mexico City 04510, Mexico
- Regenerative Medicine Laboratory, Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Coyoacan, Mexico City 04510, Mexico
| | - Leonardo I. Ruiz-Ortega
- Institute for Physical Sciences, National Autonomous University of Mexico, Cuernavaca 62210, Mexico
- Department of Biological Sciences, Columbia University, New York, NY 10027, USA
| | - Magdalena Guerra-Crespo
- Neurosciences Division, Cell Physiology Institute, National Autonomous University of Mexico, Coyoacan, Mexico City 04510, Mexico
- Regenerative Medicine Laboratory, Department of Physiology, Faculty of Medicine, National Autonomous University of Mexico, Coyoacan, Mexico City 04510, Mexico
| |
Collapse
|
2
|
Nance E, Pun SH, Saigal R, Sellers DL. Drug delivery to the central nervous system. NATURE REVIEWS. MATERIALS 2022; 7:314-331. [PMID: 38464996 PMCID: PMC10923597 DOI: 10.1038/s41578-021-00394-w] [Citation(s) in RCA: 84] [Impact Index Per Article: 42.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 10/05/2021] [Indexed: 03/12/2024]
Abstract
Despite the rising global incidence of central nervous system (CNS) disorders, CNS drug development remains challenging, with high costs, long pathways to clinical use and high failure rates. The CNS is highly protected by physiological barriers, in particular, the blood-brain barrier and the blood-cerebrospinal fluid barrier, which limit access of most drugs. Biomaterials can be designed to bypass or traverse these barriers, enabling the controlled delivery of drugs into the CNS. In this Review, we first examine the effects of normal and diseased CNS physiology on drug delivery to the brain and spinal cord. We then discuss CNS drug delivery designs and materials that are administered systemically, directly to the CNS, intranasally or peripherally through intramuscular injections. Finally, we highlight important challenges and opportunities for materials design for drug delivery to the CNS and the anticipated clinical impact of CNS drug delivery.
Collapse
Affiliation(s)
- Elizabeth Nance
- Department of Chemical Engineering, University of Washington, Seattle, WA, USA
- These authors contributed equally: Elizabeth Nance, Suzie H. Pun, Rajiv Saigal, Drew L. Sellers
| | - Suzie H. Pun
- Department of Bioengineering, University of Washington, Seattle, WA, USA
- These authors contributed equally: Elizabeth Nance, Suzie H. Pun, Rajiv Saigal, Drew L. Sellers
| | - Rajiv Saigal
- Department of Bioengineering, University of Washington, Seattle, WA, USA
- Department of Neurological Surgery, University of Washington, Seattle, WA, USA
- These authors contributed equally: Elizabeth Nance, Suzie H. Pun, Rajiv Saigal, Drew L. Sellers
| | - Drew L. Sellers
- Department of Bioengineering, University of Washington, Seattle, WA, USA
- These authors contributed equally: Elizabeth Nance, Suzie H. Pun, Rajiv Saigal, Drew L. Sellers
| |
Collapse
|
3
|
Roshani M, Kiaie N, Aghdam RM. Biomaterials and stem cells as drug/gene-delivery vehicles for Parkinson's treatment: an update. Regen Med 2021; 16:1057-1072. [PMID: 34865515 DOI: 10.2217/rme-2021-0050] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
By introducing biomaterials and stem cells into Parkinson's disease (PD), therapeutic approaches have led to promising results due to facilitating brain targeting and blood-brain barrier permeation of the drugs and genes. Here, after reviewing the most recent drug- and gene-delivery vehicles including liposomes, exosomes, natural/synthetic polymeric particles/fibers, metallic/ceramic nanoparticles and microbubbles, used for Parkinson's disease treatment, the effect of stem cells as a reservoir of neurotrophic factors and exosomes is provided.
Collapse
Affiliation(s)
- Milad Roshani
- School of Metallurgy & Materials Engineering, College of Engineering, University of Tehran, Tehran 11155-4563, Iran.,Department of Biomedical Engineering, Shahab Danesh University, Qom, Iran
| | - Nasim Kiaie
- Research Center for Advanced Technologies in Cardiovascular Medicine, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Rouhollah Mehdinavaz Aghdam
- School of Metallurgy & Materials Engineering, College of Engineering, University of Tehran, Tehran 11155-4563, Iran
| |
Collapse
|
4
|
Monge-Fuentes V, Biolchi Mayer A, Lima MR, Geraldes LR, Zanotto LN, Moreira KG, Martins OP, Piva HL, Felipe MSS, Amaral AC, Bocca AL, Tedesco AC, Mortari MR. Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson's Disease. Sci Rep 2021; 11:15185. [PMID: 34312413 PMCID: PMC8313547 DOI: 10.1038/s41598-021-94175-8] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 06/03/2021] [Indexed: 12/11/2022] Open
Abstract
Parkinson's disease (PD) is a progressive and chronic neurodegenerative disease of the central nervous system. Early treatment for PD is efficient; however, long-term systemic medication commonly leads to deleterious side-effects. Strategies that enable more selective drug delivery to the brain using smaller dosages, while crossing the complex brain-blood barrier (BBB), are highly desirable to ensure treatment efficacy and decrease/avoid unwanted outcomes. Our goal was to design and test the neurotherapeutic potential of a forefront nanoparticle-based technology composed of albumin/PLGA nanosystems loaded with dopamine (ALNP-DA) in 6-OHDA PD mice model. ALNP-DA effectively crossed the BBB, replenishing dopamine at the nigrostriatal pathway, resulting in significant motor symptom improvement when compared to Lesioned and L-DOPA groups. Notably, ALNP-DA (20 mg/animal dose) additionally up-regulated and restored motor coordination, balance, and sensorimotor performance to non-lesioned (Sham) animal level. Overall, ALNPs represent an innovative, non-invasive nano-therapeutical strategy for PD, considering its efficacy to circumvent the BBB and ultimately deliver the drug of interest to the brain.
Collapse
Affiliation(s)
- Victoria Monge-Fuentes
- Laboratório de Neurofarmacologia, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, 70910-900, Brazil.
| | - Andréia Biolchi Mayer
- Laboratório de Neurofarmacologia, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, 70910-900, Brazil
| | - Marcos Robalinho Lima
- Laboratório de Neurofarmacologia, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, 70910-900, Brazil
- Departamento de Biologia Animal e Plantas, Centro de Ciências Biológicas, Universidade Estadual de Londrina, Londrina, 86051-970, Brazil
| | - Luiza Ribeiro Geraldes
- Laboratório de Neurofarmacologia, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, 70910-900, Brazil
| | - Larissa Nepomuceno Zanotto
- Laboratório de Neurofarmacologia, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, 70910-900, Brazil
| | - Karla Graziella Moreira
- Laboratório de Neurofarmacologia, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, 70910-900, Brazil
- Laboratório de Fisiologia e Farmacologia, Universidade Federal de Catalão, Goiás, 75704-020, Brazil
| | - Olimpia Paschoal Martins
- Departamento de Química, Centro de Nanotecnologia e Engenharia de Tecidos-Fotobiologia e Fotomedicina, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, 14040-901, Brazil
| | - Henrique Luís Piva
- Departamento de Química, Centro de Nanotecnologia e Engenharia de Tecidos-Fotobiologia e Fotomedicina, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, 14040-901, Brazil
| | | | - Andre Correa Amaral
- Instituto de Saúde Pública e Patologia Tropical, Universidade Federal de Goiás, Goiânia, Goías, Brazil
| | - Anamélia Lorenzetti Bocca
- Laboratório de Imunologia Aplicada, Departamento de Biologia Celular, Instituto de Ciências Fisiológicas, Universidade de Brasília, Brasília, 70910-900, Brazil
| | - Antonio Claudio Tedesco
- Departamento de Química, Centro de Nanotecnologia e Engenharia de Tecidos-Fotobiologia e Fotomedicina, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, 14040-901, Brazil
| | - Márcia Renata Mortari
- Laboratório de Neurofarmacologia, Departamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília, 70910-900, Brazil
| |
Collapse
|
5
|
Kahana M, Weizman A, Gabay M, Loboda Y, Segal-Gavish H, Gavish A, Barhum Y, Offen D, Finberg J, Allon N, Gavish M. Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease. Mol Psychiatry 2021; 26:2626-2632. [PMID: 32372010 DOI: 10.1038/s41380-020-0742-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Revised: 03/08/2020] [Accepted: 04/20/2020] [Indexed: 02/06/2023]
Abstract
Delivery of drugs into the brain is poor due to the blood brain barrier (BBB). This study describes the development of a novel liposome-based brain-targeting drug delivery system. The liposomes incorporate a diacylglycerol moiety coupled through a linker to a peptide of 5 amino acids selected from amyloid precursor protein (APP), which is recognized by specific transporter(s)/receptor(s) in the BBB. This liposomal system enables the delivery of drugs across the BBB into the brain. The brain-directed liposomal system was used in a mouse model of Parkinson's disease (PD). Intra-peritoneal (IP) administration of liposomes loaded with dopamine (DA) demonstrated a good correlation between liposomal DA dose and the behavioral effects in hemiparkinsonian amphetamine-treated mice, with an optimal DA dose of 60 µg/kg. This is significantly lower dose than commonly used doses of the DA precursor levodopa (in the mg/kg range). IP injection of the APP-targeted liposomes loaded with a DA dose of 800 µg/kg, resulted in a significant increase in striatal DA within 5 min (6.9-fold, p < 0.05), in amphetamine-treated mice. The increase in striatal DA content persisted for at least 3 h after administration, which indicates a slow DA release from the delivery system. No elevation in DA content was detected in the heart or the liver. Similar increases in striatal DA were observed also in rats and mini-pigs. The liposomal delivery system enables penetration of compounds through the BBB and may be a candidate for the treatment of PD and other brain diseases.
Collapse
Affiliation(s)
- Meygal Kahana
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel
| | - Abraham Weizman
- Research Unit at Geha Mental Health Center and the Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, 4910002, Petah Tikva, Israel.,Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Sagol School of Neuroscience, Tel-Aviv University, 6997801, Tel Aviv, Israel
| | - Martin Gabay
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel
| | - Yelena Loboda
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel
| | - Hadar Segal-Gavish
- Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Laboratory of Neuroscience, Felsenstein Medical Research Center, 4910002, Petah Tikva, Israel.,The Child Psychiatry Division, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, 5262000, Israel
| | - Avishai Gavish
- Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Goldschleger Eye Institute, Sheba Medical Center, Tel Hashomer, 5262000, Israel
| | - Yael Barhum
- Laboratory of Neuroscience, Felsenstein Medical Research Center, 4910002, Petah Tikva, Israel
| | - Dani Offen
- Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.,Sagol School of Neuroscience, Tel-Aviv University, 6997801, Tel Aviv, Israel.,Laboratory of Neuroscience, Felsenstein Medical Research Center, 4910002, Petah Tikva, Israel
| | - John Finberg
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel
| | - Nahum Allon
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel
| | - Moshe Gavish
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, 31096, Haifa, Israel.
| |
Collapse
|
6
|
Chawla S, Kalyane D, Tambe V, Deb PK, Kalia K, Tekade RK. Evolving nanoformulation strategies for diagnosis and clinical interventions for Parkinson’s disease. Drug Discov Today 2020; 25:392-405. [DOI: 10.1016/j.drudis.2019.12.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 11/18/2019] [Accepted: 12/17/2019] [Indexed: 12/16/2022]
|
7
|
Karthivashan G, Ganesan P, Park SY, Lee HW, Choi DK. Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson's disease: From preclinical to translational studies. Biomaterials 2019; 232:119704. [PMID: 31901690 DOI: 10.1016/j.biomaterials.2019.119704] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Revised: 12/09/2019] [Accepted: 12/18/2019] [Indexed: 12/26/2022]
Abstract
The incidence of Parkinson's disease (PD), the second most common neurodegenerative disorder, has increased exponentially as the global population continues to age. Although the etiological factors contributing to PD remain uncertain, its average incidence rate is reported to be 1% of the global population older than 60 years. PD is primarily characterized by the progressive loss of dopaminergic (DAergic) neurons and/or associated neuronal networks and the subsequent depletion of dopamine (DA) levels in the brain. Thus, DA or levodopa (l-dopa), a precursor of DA, represent cardinal targets for both idiopathic and symptomatic PD therapeutics. While several therapeutic strategies have been investigated over the past decade for their abilities to curb the progression of PD, an effective cure for PD is currently unavailable. Even DA replacement therapy, an effective PD therapeutic strategy that provides an exogenous supply of DA or l-dopa, has been hindered by severe challenges, such as a poor capacity to bypass the blood-brain barrier and inadequate bioavailability. Nevertheless, with recent advances in nanotechnology, several drug delivery systems have been developed to bypass the barriers associated with central nervous system therapeutics. In here, we sought to describe the adapted lipid-based nanodrug delivery systems used in the field of PD therapeutics and their recent advances, with a particular focus placed on DA replacement therapies. This work initially explores the background of PD; offers descriptions of the most recent molecular targets; currently available clinical medications/limitations; an overview of several lipid-based PD nanotherapeutics, functionalized nanoparticles, and technical aspects in brain delivery; and, finally, presents future perspectives to enhance the use of nanotherapeutics in PD treatment.
Collapse
Affiliation(s)
- Govindarajan Karthivashan
- Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, 27478, Republic of Korea; Research Institute of Inflammatory Diseases (RID), College of Biomedical and Health Science and BK21plus Glocal Education Program of Nutraceuticals Development, Konkuk University, Chungju, 27478, Republic of Korea
| | - Palanivel Ganesan
- Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, 27478, Republic of Korea; Department of Biomedical Chemistry, Nanotechnology Research Center, Department of Applied Life Science, College of Biomedical and Health Science, Konkuk University, Chungju, 27478, Republic of Korea
| | - Shin-Young Park
- Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, 27478, Republic of Korea
| | - Ho-Won Lee
- Department of Neurology, Kyungpook National University School of Medicine and Brain Science & Engineering Institute, Kyungpook National University, Daegu, 41404, Republic of Korea
| | - Dong-Kug Choi
- Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chungju, 27478, Republic of Korea; Research Institute of Inflammatory Diseases (RID), College of Biomedical and Health Science and BK21plus Glocal Education Program of Nutraceuticals Development, Konkuk University, Chungju, 27478, Republic of Korea.
| |
Collapse
|
8
|
Cern A, Marcus D, Tropsha A, Barenholz Y, Goldblum A. New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage. J Control Release 2017; 252:18-27. [PMID: 28215669 DOI: 10.1016/j.jconrel.2017.02.015] [Citation(s) in RCA: 45] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2017] [Accepted: 02/14/2017] [Indexed: 11/17/2022]
Abstract
Remote drug loading into nano-liposomes is in most cases the best method for achieving high concentrations of active pharmaceutical ingredients (API) per nano-liposome that enable therapeutically viable API-loaded nano-liposomes, referred to as nano-drugs. This approach also enables controlled drug release. Recently, we constructed computational models to identify APIs that can achieve the desired high concentrations in nano-liposomes by remote loading. While those previous models included a broad spectrum of experimental conditions and dealt only with loading, here we reduced the scope to the molecular characteristics alone. We model and predict API suitability for nano-liposomal delivery by fixing the main experimental conditions: liposome lipid composition and size to be similar to those of Doxil® liposomes. On that basis, we add a prediction of drug leakage from the nano-liposomes during storage. The latter is critical for having pharmaceutically viable nano-drugs. The "load and leak" models were used to screen two large molecular databases in search of candidate APIs for delivery by nano-liposomes. The distribution of positive instances in both loading and leakage models was similar in the two databases screened. The screening process identified 667 molecules that were positives by both loading and leakage models (i.e., both high-loading and stable). Among them, 318 molecules received a high score in both properties and of these, 67 are FDA-approved drugs. This group of molecules, having diverse pharmacological activities, may be the basis for future liposomal drug development.
Collapse
Affiliation(s)
- Ahuva Cern
- Laboratory of Membrane and Liposome Research, Department of Biochemistry, IMRIC, The Hebrew University - Hadassah Medical School, Jerusalem, Israel; Molecular Modeling and Drug Design Laboratory, The Institute for Drug Research, The Hebrew University of Jerusalem, Israel.
| | - David Marcus
- European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, United Kingdom
| | - Alexander Tropsha
- The Laboratory for Molecular Modeling, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC, USA
| | - Yechezkel Barenholz
- Laboratory of Membrane and Liposome Research, Department of Biochemistry, IMRIC, The Hebrew University - Hadassah Medical School, Jerusalem, Israel.
| | - Amiram Goldblum
- Molecular Modeling and Drug Design Laboratory, The Institute for Drug Research, The Hebrew University of Jerusalem, Israel.
| |
Collapse
|
9
|
Mahmoudi-Badiki T, Alipour E, Hamishehkar H, Golabi SM. Dopamine-loaded liposome and its application in electrochemical DNA biosensor. J Biomater Appl 2016; 31:273-82. [PMID: 27194602 DOI: 10.1177/0885328216650378] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
In this study, disruption and lyophilization-rehydration of dopamine-loaded liposome and its application in electrochemical DNA biosensor was investigated. The liposomes containing soyphosphatidylcholine and cholesterol were prepared through thin-layer hydration. First, an investigation was carried out to find an appropriate lysing agent for disruption of prepared liposomes. Differential pulse voltammetry, as a high sensitive electrochemical technique, was used along with a multi-walled carbon nanotubes modified glassy carbon electrode for sensitive electrochemical detection of released dopamine from disrupted liposomes. Various lysing agents were investigated and finally, the disruption of liposomes using methanol was selected without any surfactant, because of its least fouling effect. Then, lyophilization of dopamine-loaded liposomes was carried out using sucrose as cryoprotectant. The electrochemical studies of lyophilized liposomes showed that the remained dopamine in sucrose-protected liposomes was higher than sucrose-free liposomes. Furthermore, sucrose has no interference in electrochemical studies. Then, with the addition of biotin-X-DHPE to liposome formulation, the lyophilized sucrose protected dopamine-loaded biotin-tagged liposomes were prepared and the feasibility of application of them in electrochemical DNA biosensor was investigated as signal enhancer and verified for detection of oligonucleotides.
Collapse
Affiliation(s)
- Tohid Mahmoudi-Badiki
- Electroanalytical Chemistry Laboratory, Department of Analytical Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran Electroanalytical Chemistry Laboratory, Department of Applied Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran
| | - Esmaeel Alipour
- Electroanalytical Chemistry Laboratory, Department of Analytical Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran
| | - Hamed Hamishehkar
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Seyed Mahdi Golabi
- Electroanalytical Chemistry Laboratory, Department of Analytical Chemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran
| |
Collapse
|
10
|
Li MH, Yu H, Wang TF, Chang ND, Zhang JQ, Du D, Liu MF, Sun SL, Wang R, Tao HQ, Geng SL, Shen ZY, Wang Q, Peng HS. Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo. J Mater Chem B 2014; 2:1619-1625. [DOI: 10.1039/c3tb21423k] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
11
|
Abdelkader H, Alani AWG, Alany RG. Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations. Drug Deliv 2013; 21:87-100. [DOI: 10.3109/10717544.2013.838077] [Citation(s) in RCA: 165] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
|
12
|
Shao M, Sun SL, Li MH, Li BX, Yu H, Shen ZY, Ren YC, Hao ZF, Chang ND, Peng HS, Yang BF. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers. J Liposome Res 2012; 22:168-76. [DOI: 10.3109/08982104.2012.668552] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
13
|
Cern A, Golbraikh A, Sedykh A, Tropsha A, Barenholz Y, Goldblum A. Quantitative structure-property relationship modeling of remote liposome loading of drugs. J Control Release 2011; 160:147-57. [PMID: 22154932 DOI: 10.1016/j.jconrel.2011.11.029] [Citation(s) in RCA: 68] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2011] [Revised: 11/21/2011] [Accepted: 11/23/2011] [Indexed: 01/29/2023]
Abstract
Remote loading of liposomes by trans-membrane gradients is used to achieve therapeutically efficacious intra-liposome concentrations of drugs. We have developed Quantitative Structure Property Relationship (QSPR) models of remote liposome loading for a data set including 60 drugs studied in 366 loading experiments internally or elsewhere. Both experimental conditions and computed chemical descriptors were employed as independent variables to predict the initial drug/lipid ratio (D/L) required to achieve high loading efficiency. Both binary (to distinguish high vs. low initial D/L) and continuous (to predict real D/L values) models were generated using advanced machine learning approaches and 5-fold external validation. The external prediction accuracy for binary models was as high as 91-96%; for continuous models the mean coefficient R(2) for regression between predicted versus observed values was 0.76-0.79. We conclude that QSPR models can be used to identify candidate drugs expected to have high remote loading capacity while simultaneously optimizing the design of formulation experiments.
Collapse
Affiliation(s)
- Ahuva Cern
- Department of Biochemistry, IMRIC, The Hebrew University-Hadassah Medical School Jerusalem, Israel
| | | | | | | | | | | |
Collapse
|
14
|
Kaplun AP, Bezrukov DA, Shvets VI. Rational design of nano- and micro-size medicinal forms of biologically active substances. APPL BIOCHEM MICRO+ 2011. [DOI: 10.1134/s0003683811080072] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
|
15
|
Carafa M, Marianecci C, Marzio LD, Caro VD, Giandalia G, Giannola LI, Santucci E. Potential dopamine prodrug-loaded liposomes: preparation, characterization, andin vitrostability studies. J Liposome Res 2009; 20:250-7. [DOI: 10.3109/08982100903384129] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
16
|
Shvets VI, Kaplun AP, Krasnopol’skii YM, Stepanov AE, Chekhonin VP. From liposomes of the 1970s to 21st century nanobiotechnology. ACTA ACUST UNITED AC 2008. [DOI: 10.1134/s1995078008110013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
17
|
Kaş HS. Drug delivery to Brain by Microparticulate Systems. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2004; 553:221-30. [PMID: 15503459 DOI: 10.1007/978-0-306-48584-8_17] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The site specific delivery of chemotherapeutic agents allows maximum concentration of an agent at a desired body site. This area specific drug delivery decreases the unwanted systemic distribution and decreases toxicity of the administered drugs. Blood-Brain Barrier (BBB) is considered to be an obstacle in delivering large number of drugs to brain. The endothelial cells forming the tubular capillaries in the brain are cemented together by intercellular tight junctions. In this way, the BBB has an important role in providing a stable extracellular environment in the central nervous system. Lack of fenestrations, very few pinocytotic vesicles, and more mitochondria are other differences of the brain capillaries which play important role in transport of drugs to brain (Fig.1). The purpose of this paper is to summarise the methods for BBB permeability modifications and to focus on various examples in delivering drugs, especially neuroncology and neuroactive drugs, to brain by microparticulate systems.
Collapse
Affiliation(s)
- H Süheyla Kaş
- Department of Pharmaceutical Technology, University of Hacettepe, Sihhiye, Ankara, Turkey
| |
Collapse
|